The TME in CRC is often characterized by chronic inflammation, where inflammatory mediators such as cytokines (e.g., TNF-α, IL-6), chemokines, and immune cells (e.g., macrophages) contribute to tumor progression and metastasis through activation of key signaling pathways, including PI3K/AKT [29,30]. This evidence concerns the gene IL6 and neoplasm.